Tumor anti-PD-L1 monoclonal antibody targeting TGF-beta1-siRNA nanoparticles and preparation method thereof

The invention provides a tumor anti-PD-L1 monoclonal antibody targeting TGF (Transforming Growth Factor)-beta 1-siRNA (Small Interference Ribonucleic Acid) nano particle and a preparation method thereof. The nano particle is formed by connecting a PD-L1 monoclonal antibody, polyethylene glycol and polycaprolactone to form a tumor anti-PD-L1 monoclonal antibody targeting drug-loading polymer PDL1-PEG-PCL and then physically wrapping TGF-beta 1-siRNA. The tumor anti-PD-L1 monoclonal antibody targeted TGF-beta1-siRNA nano particle is good in targeting property and small in toxic and side effects, and the preparation method of the tumor anti-PD-L1 monoclonal antibody targeted TGF-beta1-siRNA nano particle is simple in process, high in yield and few in side reaction..

Medienart:

Patent

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Europäisches Patentamt - (2023) vom: 31. März Zur Gesamtaufnahme - year:2023

Sprache:

Englisch

Beteiligte Personen:

WU FENGLEI [VerfasserIn]
SUN YUNLIANG [VerfasserIn]
HU NAN [VerfasserIn]
TIAN QINGSHUI [VerfasserIn]
HONG YIDONG [VerfasserIn]
ZHANG JINGZHOU [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2023-03-31, Last update posted on www.tib.eu: 2023-06-21, Last updated: 2023-06-30

Patentnummer:

CN115869424

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA017324017